Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
uniQure logo — Transforming the lives of patients through gene therapy

uniQure

Transforming the lives of patients through gene therapy

Founded 1998 The Netherlands The Netherlands 309 employees IPO Total: $1.12B Biotechnology, Pharmaceutical

General Information

Company Name uniQure
Founded Year 1998
Location The Netherlands The Netherlands +2
Employees 309
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Social

Get notified when uniQure moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

In The News Aug 25, 2026

Featured on Cnbc: HHS plans new FDA deputy commissioner roles for technology and drugs, sources sa...

Get alerts when uniQure shows new signals

About uniQure

uniQure, founded in 1998, is at the forefront of gene therapy innovation, with a commitment to transforming the lives of patients through single treatments that hold potentially curative outcomes. The company leverages a modular and validated technology platform, which fuels its rapid advancement of proprietary and partnered gene therapies aimed at alleviating severe genetic diseases.

Recently, uniQure secured a substantial $175.00 million post-IPO equity investment, led by Hercules Capital on 01 September 2025. This funding underscores the confidence investors have in the company's technology and pipeline, propelling its strategy to lead advancements in gene therapy. With its promising trajectory and strategic backing, uniQure stands as a compelling entity for investors interested in high-impact healthcare innovations.

Taxonomy: Gene Therapy, Genetic Diseases, Therapeutic Development, Modular Technology Platform, Huntington's Disease, AAV (Adeno-Associated Virus), ALS (Amyotrophic Lateral Sclerosis), Epilepsy Treatment, Fabry Disease, Proprietary Therapies, Partnerships in Healthcare, Innovative Medical Treatments, Curative Treatments

Services & Products

Innovative Cures Development
Gene Therapy Research
Clinical Trials Execution
Patient Care and Support
Regulatory Compliance

Target Customers

Patients and Families Healthcare Providers Investors Pharmaceutical Partners Regulatory Bodies

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• 1
Investor
01 Sep 2025
Post Ipo Equity •••••• - 01 Jan 2025
Post Ipo Equity •••••• - 01 Mar 2020
Post Ipo Equity •••••• - 01 Sep 2019
Post Ipo Equity •••••• - 01 May 2018

View All 12 Funding Rounds

Latest News

View All
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency — Cnbc
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
Cnbc Jun 17, 2026
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say  — Cnbc
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say 
Cnbc Aug 25, 2026

uniQure Alternatives & Competitors

View All Alternatives
uniQure vs
Genecure
Genecure

Innovative gene transfer technology aiming to combat genetic disorders, infectious diseases, and can...

Series Unknown
Biotechnology, Health Care
Compare uniQure vs Genecure
uniQure vs
Aruvant
Aruvant United States

Focused on developing innovative gene therapies for rare diseases.

7 employees
Biotechnology, Health Care
uniQure vs
Tern Therapeutics
Tern Therapeutics United States

Going to the ends of the Earth to develop new gene therapies for rare diseases

6 employees
Also compare with: uniQure vs Remedium Bio Remedium Bio uniQure vs Neurologix Neurologix View all alternatives

FAQ About uniQure

Transforming the lives of patients through gene therapy
uniQure was founded in 1998.
uniQure is headquartered in The Netherlands.
uniQure operates in the following industries: Biotechnology, Pharmaceutical.
uniQure has approximately 309 employees.
uniQure has completed 12 funding rounds, raising a total of $1.12B. The latest funding stage is IPO.
uniQure offers: Innovative Cures Development, Gene Therapy Research, Clinical Trials Execution, Patient Care and Support, Regulatory Compliance.
Top alternatives and competitors to uniQure include Genecure, Aruvant, Tern Therapeutics, Remedium Bio, Neurologix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
uniQure and Genecure are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors uniQure and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy